Macrophages in Ulcerative Colitis: Immunomodulatory Roles, Phenotypic Switching, and Therapeutic Targeting
Journal of Innate Immunity · 13.01.2026 · 18 (1) · 85-103
DOI: 10.1159/000550397 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Innate Immunity, online erschienen am 13.01.2026. Verfasst von Maojun Zhao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Critical Care Medicine, Beijing Jishuitan Hospital Guizhou Hospital, Guiyang, China. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Macrophages, Intestinal Mucosa. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background: Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by dysregulated immune responses in the gut. Macrophages, as key innate immune cells in the intestinal mucosa, play a central role in both maintaining homeostasis and driving pathology in UC. Summary: Under physiological conditions, intestinal macrophages exhibit a unique “inflammatory anergy” phenotype, supporting epithelial integrity and immune tolerance. In UC, however, persistent inflammatory signals promote monocyte recruitment and their polarization into pro-inflammatory M1-like macrophages. These cells secrete cytokines such as TNF-α, IL-1β, IL-6, and IL-12/23, produce reactive oxygen species and reactive nitrogen species, and release matrix metalloproteinases, collectively driving epithelial barrier disruption, tissue damage, and sustained inflammation. This review comprehensively discusses the origin, heterogeneity, and functional plasticity of intestinal macrophages, their dynamic interactions with other cells, and key regulatory signaling pathways – such as NF-κB, JAK-STAT, and the NLRP3 inflammasome – in UC. Key Messages: We evaluate current and emerging macrophage-targeted therapies, including cytokine blockade, chemokine receptor antagonism, phenotypic reprogramming, nanomedicine, and cell-based interventions. Furthermore, we highlight the limitations of the M1/M2 dichotomy and emphasize the need for single-cell and spatial transcriptomic approaches to better define macrophage subsets in human disease. Advancing the understanding of macrophage biology in UC will facilitate the development of precise immunomodulatory strategies and biomarker-based diagnostics, ultimately aiming to bridge the gap between mechanistic discovery and improved patient care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Critical Care Medicine, Beijing Jishuitan Hospital Guizhou Hospital, Guiyang, China.
- Department of Emergency and Critical Care Medicine, Chuzhou Integrated Traditional Chinese and Western Medicine Hospital, Chuzhou, China.
- Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
- Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Hefei, China, lujian@ahmu.edu.cn.
Zitieren
APA
Zhao, M., Yu, S., Zhang, M., Huang, Y., Dou, Z., Tian, B., Yang, L., & Lu, J. (2026). Macrophages in Ulcerative Colitis: Immunomodulatory Roles, Phenotypic Switching, and Therapeutic Targeting. Journal of Innate Immunity, 18(1), 85-103. https://doi.org/10.1159/000550397
Vancouver
Zhao M, Yu S, Zhang M, Huang Y, Dou Z, Tian B, et al. Macrophages in Ulcerative Colitis: Immunomodulatory Roles, Phenotypic Switching, and Therapeutic Targeting. Journal of Innate Immunity. 2026;18(1):85-103. doi:10.1159/000550397
BibTeX
@article{Zhao2026,
author = {Zhao, Maojun and Yu, Shaochen and Zhang, Mengjie and Huang, Yuting and Dou, Ziyue and Tian, Beibei and Yang, Langlang and Lu, Jian},
title = {Macrophages in Ulcerative Colitis: Immunomodulatory Roles, Phenotypic Switching, and Therapeutic Targeting},
journal = {Journal of Innate Immunity},
year = {2026},
volume = {18},
number = {1},
pages = {85--103},
doi = {10.1159/000550397}
}
EUVIMED